SCHEMBL3407137

SCHEMBL3407137

CCOc1cccc(CCC(=O)O)c1OC1CCCC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRA P10827 2/20 0.46
THRB P10828 2/20 0.46
PTGER4 P35408 3/20 0.43
PTGER3 P43115 3/20 0.43
PTGER2 P43116 3/20 0.43
PTGER1 P34995 2/20 0.43
GLA P06280 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTGDR Q13258 1/20 0.40
CYP2C19 P33261 1/20 0.40
LTB4R Q15722 2/20 0.39
LTB4R2 Q9NPC1 2/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
SLC16A3 O15427 1/20 0.38
SLC16A1 P53985 1/20 0.38
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3402978 0.88 THRA (0.48) THRATHRBPTGER4PTGER3PTGER2
SCHEMBL3410076 0.82 PTGER4 (0.55) THRATHRBPTGER4PTGER3PTGER2
SCHEMBL3407610 0.81 THRA (0.43) THRATHRBPTGER4PTGER3PTGER2
SCHEMBL27908885 0.80 THRA (0.50) THRATHRBPTGER4PTGER3PTGER2
SCHEMBL3405256 0.79 THRA (0.56) THRATHRBPTGER4PTGER3PTGER2
SCHEMBL1208625 0.75 L3MBTL1 (0.59) THRATHRBPTGER4PTGER3PTGER2
SCHEMBL3408740 0.75 KMT2A (0.54) PTGER4PTGER3PTGER2PTGER1KMT2A
SCHEMBL3401123 0.74 KMT2A (0.47) THRATHRBPDE4APDE4BPDE4C
SCHEMBL27926791 0.72 PTGDR (0.58) THRATHRBPTGDRLTB4RLTB4R2
SCHEMBL3402981 0.72 THRA (0.58) THRATHRBPTGER4PTGER3PTGER2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8487121-B2 Chromane derivatives as TRPV3 modulators GLENMARK PHARMACEUTICALS S.A. (CH) 2013-07-16 US disclosed
CN-103183660-A Chromane derivative used as TRPV3 (transient receptor potential vanilloid 3) conditioning agent GLENMARK PHARMACEUTICALS SA 2013-07-03 CN disclosed
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS S.A. (CH) 2010-12-09 US disclosed
EP-2254879-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS Glenmark Pharmaceuticals S.A. (CH) 2010-12-01 EP disclosed
WO-2009084034-A2 CHROMANE DERIVATIVES AS TRPV3 MODULATORS GLENMARK PHARMACEUTICALS, S. A. (CH) 2009-07-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100311778-A1 CHROMANE DERIVATIVES AS TRPV3 MODULATORS TRPV3, TRPV2, TRPV1 THRA 530/4885THRB 662/4885PTGER4 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.